

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SUNSHINE LAKE PHARMA CO., LTD.**

**廣東東陽光藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6887)**

**INSIDE INFORMATION**  
**EQUITY TRANSFERS BETWEEN MEMBERS OF THE GROUP OF**  
**CONTROLLING SHAREHOLDERS**

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).


**THE EQUITY TRANSFERS**

The board of directors (the “**Directors**”) of the Company (the “**Board**”) has been informed by Mr. Zhang Yushuai (張寓帥) (“**Mr. Zhang**”) and Ms. Guo Meilan (郭梅蘭) (“**Ms. Guo**”), each a member of the group of controlling shareholder (as defined under the Listing Rules) of the Company (the “**Controlling Shareholder(s)**”), that due to Ms. Guo’s decision to retire and reduce her involvement in the Group’s business, on 29 December 2025, Mr. Zhang and Ms. Guo entered into equity transfer agreements, pursuant to which Ms. Guo shall transfer 71.75% equity interest in Ruyuan Yao Autonomous County Yuneng Electric Industrial Co., Ltd.\* (乳源瑤族自治縣寓能電子實業有限公司) (“**Ruyuan Yuneng Electric**”) and 74.63% equity interest in Ruyuan Yao Autonomous County Xinjing Technology Development Co., Ltd.\* (乳源瑤族自治縣新京科技發展有限公司) (“**Ruyuan Xinjing Technology**”) held by her, respectively, to Mr. Zhang each for a nominal consideration of RMB1.00 (the “**Equity Transfers**”). Ms. Guo is the mother of Mr. Zhang.


Upon the completion of the relevant regulatory filings and the completion of the Equity Transfers, Mr. Zhang will hold 99.2% and 75.0% equity interest in Ruyuan Yuneng Electric and Ruyuan Xinjing Technology, respectively, thereby becoming the new leader of the group of Controlling Shareholders, and Ms. Guo will cease to be a member of the group of Controlling Shareholders.

The Directors believe that the Equity Transfers will not have any adverse impact on the finance and operation of the Company as a whole.

Prior to the Equity Transfers, the shareholding structures of the Company is set out as follows:



Upon completion of the Equity Transfers, the shareholding structure of the Company will be as follows:



## IMPLICATIONS UNDER TAKEOVERS CODE

As Mr. Zhang will become the new leader of the group of Controlling Shareholders upon completion of the Equity Transfers, the Equity Transfers will trigger an obligation on the part of Mr. Zhang to make a mandatory general offer for all the issued shares of the Company pursuant to Note 6(a)(1) to Rule 26.1 of the Code on Takeovers and Mergers (“**Takeovers Code**”) unless a waiver is granted by the executive director of the Corporate Finance division of the Securities and Futures Commission of Hong Kong (or his delegates) (the “**Executive**”). Accordingly, Mr. Zhang has applied for, and the Executive has granted to Mr. Zhang, a waiver from the obligation to make a mandatory general offer as a result of the Equity Transfers.

**Shareholders of the Company and the public are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Sunshine Lake Pharma Co., Ltd.**  
**Dr. ZHANG Yingjun**  
*Chairman*

Dongguan, the PRC  
29 December 2025

*As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.*

\* *For identification purpose only*